Kisspeptin (Kisspeptin-10)

Comprehensive Research Analysis - Master Regulator of Reproductive Hormone Axis & Fertility

Classification: Reproductive Neuropeptide, GnRH Secretagogue, KISS1R Agonist Amino Acid Sequence: 10 amino acids (C-terminal fragment of Kisspeptin-54) Chemical Formula: Variable (depends on specific fragment) Molecular Weight: ~1,302 Da (Kisspeptin-10) Research Status: Extensive clinical trials in fertility and reproductive disorders WADA Status: No specific prohibition

1. Executive Summary

Kisspeptin is a product of the KISS1 gene, cleaved from an initial 145-amino-acid protein to produce active fragments including kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10. These N-terminally truncated peptides belong to the RFamide family, all sharing a common arginine-phenylalanine-NH₂ motif at their C-terminus. The 10-amino-acid C-terminus peptide (KP-10) is well-conserved and binds to KISS1R.

Master Reproductive Regulator: Kisspeptin is the leading upstream regulator of pulsatile and surge gonadotropin-releasing hormone (GnRH) secretion in the hypothalamus, serving as the key governor of the hypothalamic-pituitary-ovary axis. Kisspeptin-GPR54 signaling plays a crucial role in initiating GnRH secretion at puberty, and mutations in KISS1R result in hypogonadotropic hypogonadism.

Clinical Applications: Single administration of kisspeptin-54 induced egg maturation in women undergoing IVF, with pregnancy rates of 23-37% in randomized trials. Kisspeptin-54 demonstrated 63% biochemical pregnancy and 45% live birth rates per transfer at therapeutic doses.

Goal Relevance:

Enhance fertility and improve chances of conception for individuals undergoing IVF treatment.
Support reproductive health by regulating hormone levels and improving ovulation timing.
Aid in the management of reproductive disorders related to hormone imbalances.
Boost libido and sexual wellness by optimizing reproductive hormone function.
Assist in the onset of puberty for those experiencing delayed puberty due to hormonal issues.
Improve egg maturation and follicular development for better reproductive outcomes.
Provide support for individuals with hypogonadotropic hypogonadism by enhancing hormone secretion.

2. Chemical Structure & Composition

Kisspeptin Precursor & Fragments

Prepro-Kisspeptin: 145 amino acids total

19-amino-acid signal peptide
Central 54-amino-acid region → Kisspeptin-54 (Kp-54, formerly "metastin")

Active Fragments:

Kisspeptin-54 (KP-54): 54 amino acids, C-terminally amidated - major circulating form
Kisspeptin-14 (KP-14): 14 amino acids
Kisspeptin-13 (KP-13): 13 amino acids
Kisspeptin-10 (KP-10): 10 amino acids - minimal active fragment

Molecular Weight:

KP-54: ~5,850 Da
KP-10: ~1,302 Da

Structural Characteristics

RFamide Family: All kisspeptin fragments share common arginine-phenylalanine-NH₂ (RF-NH₂) motif at C-terminus.

Conserved C-Terminal Region: The 10-amino-acid C-terminus is well-conserved across species and represents the minimal sequence required for KISS1R binding and activation.

NMR Structural Analysis: KP-10 exhibits helicoidal structure between Asn(4) and Tyr(10) residues, with mixed α-helix and 3₁₀-helix characteristics.

Original Name: Initially called "metastin" after its role as metastasis suppressor, now standardized as kisspeptin.

3. Mechanism of Action

Primary Mechanism: GnRH Stimulation via KISS1R

Direct GnRH Neuron Activation:

Kisspeptin binds KISS1R (GPR54) on GnRH neurons
Central administration produces dramatic GnRH release into cerebrospinal fluid
Parallel rise in serum LH demonstrates direct action at GnRH release level

Hypothalamic-Pituitary-Gonadal (HPG) Axis Control

Kisspeptin acts upstream of GnRH, integrating:

Paracrine stimulatory/inhibitory inputs from neurokinin B and dynorphin (KNDy neuropeptides)
Sex steroid feedback (estrogen, testosterone)
Metabolic status signals

Downstream Effects:

Pulsatile GnRH secretion → hypothalamus
LH and FSH release → anterior pituitary
Sex hormone synthesis → gonads (estrogen, progesterone, testosterone)

Role in Female Reproduction

Critical regulator modulating multiple aspects:

Gonadotropin secretion control
Follicular development
Oocyte maturation
Ovulation timing
Puberty onset (acts as "molecular switch for puberty")

Additional Mechanisms

Ovarian Expression: KISS1/KISS1R system also expressed directly in ovary, suggesting local autocrine/paracrine actions.

Metastasis Suppression: Original discovery showed anti-metastatic properties in cancer cells (hence name "metastin").

4. Pharmacokinetics

Half-Life (Critical Difference Between Fragments)

Kisspeptin-10 (KP-10):

Human: ~4 minutes plasma half-life
Specific: 3.8 ± 0.3 minutes in healthy men
7-fold shorter than KP-54

Kisspeptin-54 (KP-54):

Human: ~28 minutes terminal half-life
Alternative measurement: 27.6-32 minutes
Major circulating form of kisspeptin in humans

MVT-602 (TAK-448 - Agonist):

Prolonged duration: 21-22 hours (vs 4.7h for KP-54)
Stronger pharmacodynamic effect than natural KP-54

Stability & Degradation

KP-10 Decomposition Half-Lives:

4°C: 6.8 minutes
25°C: 2.9 minutes
37°C: 1.7 minutes
Conclusion: Degrades rapidly, requiring careful handling

Clinical Pharmacology

KP-54 vs KP-10 Potency:

KP-54 more potent at eliciting sustained LH release
KP-54 can cross blood-brain barrier; KP-10 cannot
Better pharmacokinetic profile for KP-54 in bloodstream

Clinical Utility Limitation: Short circulating half-life of natural kisspeptins limits therapeutic utility, driving development of longer-acting analogs like MVT-602.

5. Dosing Protocols

IVF Ovulation Induction (Kisspeptin-54)

Optimal Dosing Range:

Minimal Effective: 1.6 nmol/kg SC (proved insufficient in trials)
Therapeutic Range: 6.4-12.8 nmol/kg SC
Optimal Efficacy: 12.8 nmol/kg SC
Timing: 36 hours after final gonadotropin injection

Phase 2 Adaptive Trial:

3.2 nmol/kg (n=5)
6.4 nmol/kg (n=20)
9.6 nmol/kg (n=15)
12.8 nmol/kg (n=20)

Hypothalamic Amenorrhea Treatment

Established Protocol:

Dose: 6.4 nmol/kg subcutaneously
Frequency: Twice weekly
Duration: 8 weeks
Monitoring: LH and FSH levels

Research/Experimental Dosing

Intravenous Bolus (KP-10):

0.3, 1.0, 3.0, or 10 nmol/kg IV bolus
Used in clinical pharmacology studies

Continuous IV Infusion:

1 nmol/kg/hour for 75 minutes
Employed for hypoactive sexual desire disorder studies

Intranasal Administration:

Recently demonstrated rapid gonadotropin stimulation
Well-tolerated, no adverse events

Administration

Routes: Subcutaneous (clinical), intravenous (research), intranasal (experimental) Sites (SC): Abdomen, thigh Timing: Protocol-dependent; IVF trigger at specific cycle timepoint

6. Clinical Research & Evidence

IVF & Ovulation Induction

Landmark JCI Study - Egg Maturation: Single dose kisspeptin-54 triggered oocyte maturation in IVF patients

Phase 2 OHSS Prevention:

Kisspeptin-54 used to trigger ovulation in women at high risk of ovarian hyperstimulation syndrome (OHSS)
Pregnancy rates: 23-37% across randomized trials
At all doses: 63% biochemical pregnancy, 53% clinical pregnancy, 45% live birth per transfer

Reproductive Function Studies

LH Stimulation in Men:

Kisspeptin-10 is potent stimulator of LH
Increases LH pulse frequency
No adverse events reported

Sexual Dimorphism Study:

KP-10 effects on reproductive hormone release show sex-specific differences
Dose range: 0.3-10 nmol/kg IV

Sexual Function Disorders

HSDD in Women (JAMA Network):

Randomized clinical trial of kisspeptin for hypoactive sexual desire disorder
Well-tolerated, no adverse events

HSDD in Men:

Effects on sexual brain processing and penile tumescence
No side effects or adverse events reported
No significant effects on blood pressure or heart rate

Intranasal Administration

Recent eBioMedicine Publication:

Intranasal kisspeptin rapidly stimulates gonadotropin release
Well-tolerated by all participants
No side effects or adverse events of any severity

Large-Scale Safety Data

>1,000 Participants Safety Profile: Prior clinical trials administered kisspeptin IV and SC to over 1,000 healthy men and women, plus patients with reproductive and psychosexual disorders, without observed adverse effects.

7. Safety Profile

Clinical Trial Safety

Excellent Tolerability:

Reported Side Effects (Research Chemical Use)

Transient Tolerance Symptoms: After first few doses, some users report:

Nausea, vomiting, diarrhea
Headache
Increased sweating
Postural dizziness
Hot flashes

Severity: Relatively common but short-lived, typically do not require medical intervention

FDA Safety Concerns

Immunogenicity Risk: FDA expressed concerns about:

Potential immunogenicity when formulated for SC/IM injection
Longer amino acid chain structure
Potential peptide-related impurities
Aggregate formation

Category 2 Classification: FDA classifies kisspeptin-10 as presenting "substantial safety risks" for compounding

Additional Concerns

Receptor Desensitization: Can occur with excessive frequency of use

Cardiovascular Effects:

Can cause blood vessel constriction
Potential concern for people with heart disease
Affects circulation

Long-Term Safety Unknown: Risks over months or years remain unclear

Overall Assessment

Clinical Trials: Excellent safety profile with no adverse events in controlled settings over short-term use.

FDA Perspective: Concerns about compounded formulations, immunogenicity, and lack of long-term data.

8. Administration & Practical Application

Routes: Subcutaneous (clinical), intravenous (research), intranasal (experimental) Sites (SC): Abdomen, thigh (rotate sites) Reconstitution: Typically bacteriostatic water for lyophilized powder Injection Technique:

Insulin syringes for SC administration
Alcohol swab injection site
Inject slowly

IVF Protocol Application

Timing:

Administer 36 hours after final gonadotropin injection
Replace traditional hCG trigger in high OHSS-risk patients
Single dose per cycle

Monitoring:

Follicle ultrasound
Estradiol levels
Post-trigger: oocyte retrieval 36 hours later

Hypothalamic Amenorrhea Protocol

Schedule:

Twice weekly SC injections
8-week treatment course
Monitor LH/FSH response
Assess menstrual cycle restoration

Storage & Handling

Critical Stability Considerations:

KP-10 degrades rapidly at room temperature (1.7 min half-life at 37°C)
Refrigeration essential
Protect from light
Use reconstituted solution quickly

9. Storage & Stability

Lyophilized Powder (Unreconstituted):

Store at -20°C (freezer) for long-term
2-8°C (refrigerator) short-term acceptable
Protect from light and moisture

Reconstituted Solution:

CRITICAL: Rapid degradation at room temperature
Store at 2-8°C immediately after reconstitution
Use within 7-14 days maximum
Do NOT freeze
Protect from light

Temperature Sensitivity:

Conclusion: Kisspeptin requires stringent cold-chain management due to rapid degradation.

Reviewed potential for Section 503A Bulk Drug Substances List
Safety concerns noted

Clinical Trial Status:

Multiple ongoing studies registered at ClinicalTrials.gov
NCT00914823: Kisspeptin Administration in Adults

WADA Status: No specific prohibition for athletic use (not listed on WADA Prohibited List as of 2025)

International Status: Not approved for therapeutic use in major jurisdictions (US, EU, Canada, Australia)

11. Product Cross-Reference

Core Peptides Equivalent: Product page inaccessible during research; verify availability at https://www.corepeptides.com/product/kisspeptin-10/

Typical Research Specifications:

Form: Lyophilized powder
Purity: >98% (HPLC)
Common Sizes: 2mg, 5mg, 10mg vials
Storage: -20°C

Epiq Aminos: Product availability and pricing to be confirmed via https://orange-shrew-635172.hostingersite.com/

Alternative Peptide Sciences: Kisspeptin-10 available at Peptide Sciences - 99% purity, USA-made

MVT-602 (TAK-448): Longer-acting kisspeptin receptor agonist in development by Myovant Sciences - proprietary pharmaceutical, not available as research chemical

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

High dosages of bpc 157 the typical therapeutic doses that are prescribed are anywhere from 300 to 500 micrograms subcutaneously maybe two or three times per week and that is typically done for a cou
t I made earlier which is that bpc 157 is typically taken in these dosages of about 300 to 500 micrograms two to three times per week maybe even five days per week if you're going to

Stacking Insights

irtue of acronyms and numbers bpc 157 or mk677 etc such that if you're not really familiar with them it can be a bit overwhelming and Confused today I'm going to provide a very simple organiz
mental health goals I'd be remiss if I didn't say at the outset here that a lot of what's happening with applied therapeutic peptide biology falls into one of three categories there are peptides that

12. References & Citations

Document Version: 1.0 Last Updated: December 23, 2025 Development Status: Research Peptide; NOT FDA-Approved Regulatory Status: FDA Category 2 (Safety Concerns for Compounding)